Last checked at 5 Jun 2017 07:00
ECO Animal Health Group plc (AIM: EAH)
ECO RECEIVES MALAYSIAN MARKETING AUTHORISATION FOR AIVLOSIN® FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the National Pharmaceutical Regulatory Agency of Malaysia for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption.
This approval, the second in Southeast Asia, follows the European approval received in June 2016. ECO will start selling Aivlosin® in Malaysia for the medication of drinking water for the treatment of infections caused by Mycoplasma in poultry laying eggs for human consumption, with a zero day drug withdrawal period for eggs.
ECO has begun the process of submitting the Aivlosin® regulatory files for the treatment of layers in numerous other key egg producing markets.
Aivlosin®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
Peter Lawrence, Chairman of ECO, commented “This approval is another important step in the development of Aivlosin® for commercial layers. Malaysia is ranked as a global top twenty egg producing country and home to four of the ten largest egg producers in Asia. This latest approval demonstrates ECO’s continued progress to becoming a major force in the international market for veterinary pharmaceutical products.”
This announcement contains inside information.
Contacts:
ECO Animal Health Group plc
| Peter Lawrence | 020 8336 6190 | |
| Marc Loomes | 020 8447 6906 | |
| Spiro Financial | ||
| Anthony Spiro | 020 8336 6196 | |
| Peel Hunt LLP (Nominated Adviser) | ||
| Dan Webster, Adrian Trimmings, George Sellar | 020 7418 8900 | |
| N+1 Singer (Joint Broker) | 020 7496 3000 | |
| Mark Taylor, Brough Ransom |
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders
View source version on businesswire.com: http://www.businesswire.com/news/home/20170604005005/en/
Copyright Business Wire 2017